Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 61Neoplasms 35Colorectal Neoplasms 32Neoplasm Metastasis 31Breast Neoplasms 30Prostatic Neoplasms 26Pancreatic Neoplasms 26Ovarian Neoplasms 26Recurrence 25Multiple Myeloma 25Melanoma 23Squamous Cell Carcinoma of Head and Neck 22Precursor Cell Lymphoblastic Leukemia-Lymphoma 18Triple Negative Breast Neoplasms 17Endometrial Neoplasms 17Lymphoma, Large B-Cell, Diffuse 16Lung Neoplasms 16Glioblastoma 16Lymphoma, Non-Hodgkin 15Leukemia, Myeloid, Acute 14Burkitt Lymphoma 14Stomach Neoplasms 13Small Cell Lung Carcinoma 12Colonic Neoplasms 12Carcinoma, Renal Cell 12Uterine Cervical Neoplasms 11Lymphoma 11Glioma 11Gastrointestinal Neoplasms 11Lymphoma, Follicular 10

Interventions

tucatinib 1trastuzumab biosimilar HLX02 1ribociclib 1pertuzumab 1Trastuzumab 1PF-05280014 1Ontruzant 1Ogivri 1Fulvestrant 1Docetaxel 1Carboplatin 12C4 antibody 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Anatomic Stage II Breast Cancer AJCC v8 × 30 days × Clear all
NCT05319873 2026-05-11

Ribociclib, Tucatinib, and Trastuzumab for the Treatment of HER2 Positive Breast Cancer

Jonsson Comprehensive Cancer Center

Phase 1/2 Active not recruiting
18 enrolled
Breast

Anatomic Stage II Breast Cancer AJCC v8

Data powered by HemOnc (CC BY 4.0) Colophon âš¡